FDA Grants Oncolyze Orphan Drug Designation for Leukemia Treatment
FDA granted Oncoloze’s OM-301 an orphan drug designation for the treatment of acute myeloid leukemia (AML).
Oncolyze, a biopharmaceutical company specializing in cancer therapeutics, announced on Jan. 5, 2022, that FDA has granted the company an orphan drug designation. The designation was granted to the company’s preclinical drug candidate, OM-301, for acute myeloid leukemia (AML).
OM-301 is a therapeutic in pre-clinical development intended for the treatment of blood cancers. Acute myeloid leukemia is a rare form of cancer that has approximately 20,000 new cases each year, according to a company press release.
"We are actively fundraising to advance OM-301 into clinical trials. The orphan drug designation is an important milestone that further validates our efforts to investigate the value of OM-301 as a potentially groundbreaking therapy for patients with AML and other cancers," said Steven Evans, co-founder and CEO of Oncolyze, in the press release.
Source: Oncolyze
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
